Supranuclear Palsy malady

Wikipedia: Progressive supranuclear palsy (PSP) (or the Steele-Richardson-Olszewski syndrome, after the Canadian...⁴⁴ more...

MalaCards: Supranuclear Palsy, also known as supranuclear paralysis, is related to progressive supranuclear palsy and parkinson's disease. An important gene associated with Supranuclear Palsy is MAPT (microtubule-associated protein tau), and among its related pathways are Apoptosis and survival Role of CDK5 in neuronal death and survival and Development Leptin signaling via JAK/STAT and MAPK cascades. The compounds carbachol and levodopa have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and cortex, and related mouse phenotypes are endocrine/exocrine gland and respiratory system.

supranuclear palsy 7 supranuclear paralysis 43

Diseases related to supranuclear palsy by text searches and GeneDecks gene sharing:

(show top 50)    (show all 400)

id	Related Disease	Score	Top Affiliating Genes
1	progressive supranuclear palsy	39.2	PARK7, PARK2, CHAT, CDK5, APOE, APP
2	parkinson's disease	36.1	PARK7, MAPT, SNCA, GBA
3	alzheimer's disease	34.6	APOE, APP, MAPT, PRNP
4	corticobasal degeneration	34.0	MYC, MAPT, MAPK3, MAPK1, HSPB2, CASP3
5	tauopathy	31.3	PARK7, PARK2, CDK5, APP, MAPT, SNCA
6	parkinsonian disorders	30.9	MAPT, SLC6A3, NEFL
7	pick's disease	30.9	RD3, MYC, PARK7, CHAT, MTA2, APOE
8	multiple system atrophy	30.6	PARK7, PARK2, CHAT, MTAP, CDK5, APOE
9	aphasia	30.1	APOE, APP, MAPT, SNCA, RPS27A, LRRK2
10	paralysis	29.1	PARK2, BCHE, MAPT, DRD2, SNCA, RPS27A
11	was-related disorders	28.7	PARK7, CHRM2, APOE, APP, MAPT, HRAS
12	frontotemporal dementia	26.8	PARK2, BCHE, YWHAQ, MTA2, APOE, APP
13	dementia	25.6	VEGFA, PARK7, PARK2, BCHE, CHRM2, CHAT
14	cervicitis	25.4	VEGFA, MYC, PARK7, PARK2, CDK5, MIR132
15	neurodegeneration	24.8	VEGFA, PARK7, PARK2, BCHE, CHAT, CDK5
16	neurodegenerative disease	24.2	PARK7, PARK2, BCHE, CHAT, CHRM1, CDK5
17	cerebritis	21.1	VEGFA, MYC, PARK7, PARK2, BCHE, CHRM2
18	neuronitis	20.1	VEGFA, MYC, PARK7, PARK2, BCHE, CHRM2
19	semantic dementia	13.9	APOE, MAPT, RPS27A
20	rem sleep behavior disorder	13.9	SNCA, RPS27A, ACHE, SLC6A3
21	sepiapterin reductase deficiency	13.8	PARK2, DRD2, TH, SLC6A3
22	focal dystonia	13.8	PARK2, DRD2, NDUFS4
23	neuronal intranuclear inclusion disease	13.8	MAPT, SNCA, RPS27A, NSF
24	gangliocytoma	13.8	TH, PVALB, SYP
25	parkinson disease 10	13.8	PARK7, PARK2, SNCA, LRRK2
26	parkinson disease type 3	13.8	PARK7, PARK2, MAPT, SNCA, LRRK2
27	cerebral atrophy	13.7	APOE, MAPT, RPS27A, GFAP
28	gaze palsy	13.7	MAPT, SNCA, GBA
29	striatonigral degeneration	13.7	MAP2, DRD2, SNCA, RPS27A, SLC6A3
30	major affective disorder	13.7	HTR3A, DRD2, TH
31	manic-depressive illness	13.7	HRAS, DRD2, TH, SLC6A3
32	alzheimer disease type 1	13.7	APOE, APP, MAPT
33	nicotine dependence	13.7	CHAT, CHRM1, DRD2, TH, SLC6A3
34	essential tremor	13.7	PARK2, SNCA, LRRK2, SLC6A3, GBA
35	neuroaxonal dystrophy	13.7	SNCA, RPS27A, NGF
36	early-onset familial alzheimer disease	13.7	APP, MAPT, SNCA
37	binswanger's disease	13.7	APOE, APP, ACHE
38	inclusion body myositis	13.7	APP, MAPT, RPS27A
39	striatal degeneration	13.6	NGF, TH, SLC6A3
40	phenylketonuria	13.6	HTR3A, DRD2, ACHE, HCRT, TH, SLC6A3
41	poliomyelitis	13.6	CHAT, RPS27A, SYP, CS
42	niemann-pick disease type c1	13.6	APP, MAPT, SNCA, HCRT, NPC1
43	olivopontocerebellar atrophy	13.6	MAPT, GLUD1, SNCA, RPS27A, PRNP
44	aneurysmal bone cysts	13.6	CDK5, MAPT, SLCO1A2
45	movement disease	13.6	PARK7, PARK2, MAPT, DRD2, SNCA, RPS27A
46	alzheimer disease type 2	13.6	BCHE, APOE, APP, MAPT
47	social phobia	13.6	HTR1A, HTR3A, DRD2
48	low compliance bladder	13.6	CHRM2, CHRM1, NGF
49	drug addiction	13.6	MAPK1, DRD2, NTS, HCRT, SLC6A3
50	primary progressive aphasia	13.5	APP, MAPT, LRRK2, PRNP

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to supranuclear palsy:

²²

MGI Mouse Phenotypes related to supranuclear palsy:

²⁵ (show all 20)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	10.0	LRRK2, CRHR1, GLUD1, IL2
2	respiratory system phenotype	MP:0005388	9.9	NDUFS4, TH, HCRT, ACHE, LRRK2, CHRM1
3	taste/olfaction phenotype	MP:0005394	9.7	SNCA, CASP3, MAPT, MAPK1, DRD2, SLC6A3
4	hematopoietic system phenotype	MP:0005397	9.3	CD8B, MTA2, IRF4, IL21, CSF3, LRRK2
5	liver/biliary system phenotype	MP:0005370	9.1	GBA, CHRM2, CHRM4, MTA2, IL2, DRD2
6	no phenotypic analysis	MP:0003012	9.0	CDK5, NTS, DRD2, HRAS, LRRK2, VEGFA
7	renal/urinary system phenotype	MP:0005367	9.0	HTR3A, MAPT, APOE, MTA2, CHRM2, CASP3
8	skeleton phenotype	MP:0005390	8.2	MYC, ACP2, NDUFS4, EIF2AK3, VEGFA, SNCA
9	immune system phenotype	MP:0005387	8.1	GFAP, ACP2, EIF2AK3, LRRK2, NDUFS4, HIST1H1E
10	reproductive system phenotype	MP:0005389	7.9	APP, CASP3, HRAS, SNCA, ACHE, HIST1H1E
11	integument phenotype	MP:0010771	7.7	CHRM2, NDUFS4, HRAS, HTR3A, MAPT, APP
12	muscle phenotype	MP:0005369	7.7	VEGFA, SLC6A3, CHAT, MYC, PARK2, CHRM2
13	normal phenotype	MP:0002873	7.0	CRHR1, HIST1H1E, NDUFS4, MYC, CHAT, CDK5
14	cardiovascular system phenotype	MP:0005385	6.6	HTR1A, CASP3, HRAS, DRD2, SNCA, NDUFS4
15	cellular phenotype	MP:0005384	5.9	LRRK2, EIF2AK3, GFAP, PVALB, PRNP, NPC1
16	nervous system phenotype	MP:0003631	5.1	GBA, EIF2AK3, LRRK2, NDUFS4, NGF, SMURF2
17	mortality/aging	MP:0010768	5.0	CRHR1, SMURF2, SNCA, DDB2, DRD2, HSPB2
18	behavior/neurological phenotype	MP:0005386	4.3	CHRM2, CHAT, CHRM1, CHRM4, MOBP, CDK5
19	homeostasis/metabolism phenotype	MP:0005376	4.3	VEGFA, EIF2AK3, LRRK2, NDUFS4, CRHR1, SNCA
20	growth/size phenotype	MP:0005378	3.3	VEGFA, MYC, PARK7, PARK2, CHRM2, CHAT

Articles related to supranuclear palsy:

(show top 50)    (show all 155)

id	Title	Authors	Year	Affiliating Genes
1	Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease. (21568901)	Borroni B.... Padovani A.	2011	MAPT
2	MicroRNA-132 loss is associated with tau exon 10 incl usion in progressive supranuclear palsy. (21807765)	Smith P.Y.... HAcbert S.S.	2011	MAPT, MIR132
3	Glucocerebrosidase mutations p.L444P and p.N370S are not associated with multisystem atrophy, progressive supranuclear palsy and cor ticobasal degeneration in Polish patients. (19882201)	Jamrozik Z.... Kwiecinski H.	2010	GBA
4	A comparison of changes in proteasomal subunit expres sion in the substantia nigra in Parkinson's disease, multiple system atrophy an d progressive supranuclear palsy. (20176003)	Bukhatwa S.... Jenner P.	2010	GFAP
5	Rivastigmine for the treatment of dementia in patient s with progressive supranuclear palsy: Clinical observations as a basis for pow er calculations and safety analysis. (20129321)	Liepelt I.... Berg D.	2010	BCHE
6	Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. (18989114)	Josephs K.A.... Duffy J.R.	2008	MAPT
7	Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy. (17534953)	Warren N.M.... Burn D.J.	2007	DRD2, SLC6A3
8	Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. (17357082)	Melquist S.... Stephan D.A.	2007	MAPT, ACP2, DDB2
9	Effect of MAPT and APOE on prognosis of progressive supranuclear palsy. (16839689)	Baba Y.... Dickson D.W.	2006	MAPT, APOE
10	Relationship between neuronal loss and tangle formation in neurons and oligodendroglia in progressive supranuclear palsy. (16521479)	Jin C.... Matsumoto M.	2006	MAPT
11	Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. (16908744)	Seppi K.... Poewe W.	2006	SLC6A3
12	Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. (16092076)	Scaravilli T.... Ferrer I.	2005	MAPT
13	A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. (16014651)	Halliday G.M.... Henderson J.M.	2005	MAPT, RPS27A
14	Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. (15293277)	Pastor P.... Goate A.M.	2004	MAPT, NSF, CRHR1
15	Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans. (15050720)	Hope A.D.... de Silva R.	2004	RPS27A
16	Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. (14969740)	Gibb G.M.... Hanger D.P.	2004	MAPT
17	Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear palsy. (14991828)	Oliva R.... Pastor P.	2004	MAPT
18	Tau epitope display in progressive supranuclear palsy and corticobasal degeneration. (15475684)	Berry R.W.... Binder L.I.	2004	MAPT
19	Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. (14502669)	Josephs K.A.... Dickson D.W.	2003	APOE
20	Excessive daytime sleepiness and low CSF orexin-A/hypocretin-I levels in a patient with probable progressive supranuclear palsy (14870576)	Hattori Y.... Kanbayashi T.	2003	HCRT
21	APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy. (12552038)	Tsuboi Y.... Dickson D.W.	2003	APOE
22	Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. (12200627)	Togo T.... Dickson D.W.	2002	GFAP
23	Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. (12410379)	Ferrer I.... Puig B.	2002	MAPT
24	An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. (12325083)	Poorkaj P.... Schellenberg G.D.	2002	MAPT
25	Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsy. (11303763)	Arai T.... Takamatsu J.	2001	MAPT
26	Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy. (11601500)	Liu W.K.... Dickson D.W.	2001	MAPT
27	Phosphorylated c-MYC expression in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. (11679086)	Ferrer I.... Puig B.	2001	MYC, CASP3
28	Cortical synapse loss in progressive supranuclear palsy. (11379815)	Bigio E.H.... Hutton M.	2001	SYP
29	Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. (11303790)	Ferrer I.... Ribalta T.	2001	HRAS, MAPK3, MAPK1
30	Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. (11271372)	Arai T.... McGeer P.L.	2001	MAPT
31	Progressive supranuclear palsy. (11724919)	Tawana K.... Ramsden D.B.	2001	MAPT
32	Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. (11746433)	Park L.C.... Gibson G.E.	2001	GLUD1
33	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. (10775534)	Stanford P.M.... Schofield P.R.	2000	MAPT
34	Mutational analysis of the tau gene in progressive supranuclear palsy. (10534245)	Higgins J.J.... Loveless J.M.	1999	MAPT
35	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. (10530520)	Bonifati V.... Heutink P.	1999	MAPT
36	The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. (10209184)	Morris H.R.... Wood N.W.	1999	MAPT
37	A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration. (9932968)	Higgins J.J.... Loveless J.M.	1999	MAPT
38	Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans. (10580705)	Ezquerra M.... Oliva R.	1999	MAPT
39	A human tyrosine hydroxylase isoform associated with progressive supranuclear palsy shows altered enzymatic activity. (9920892)	Bodeau-Pean S.... Dumas S.	1999	TH
40	The internal globus pallidus is affected in progressi ve supranuclear palsy and Parkinson's disease. (10448425)	Hardman C.D.... Halliday G.M.	1999	PVALB
41	Clinical and genetic aspects of progressive supranuclear palsy. (9877531)	Litvan I.... Hutton M.	1998	MAPT
42	Progressive supranuclear palsy, diagnostic problems in the light of own case (10358839)	Kulczycki J.... Kuran W.	1998	MAPT
43	Direct genetic evidence for involvement of tau in progressive supranuclear palsy. European Study Group on Atypical Parkinsonism Consortium. (9781517)	Bennett P.... Williams A.C.	1998	MAPT
44	Apolipoprotein E in progressive supranuclear palsy in Japan. (9246676)	Sawa A.... Matsushita M.	1997	APOE
45	Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. (7964681)	Arnold G.... Kirsch C.M.	1994	DRD2
46	Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. (8489409)	Van Royen E.... Janssen A.G.	1993	DRD2
47	CSF galanin and neuropeptide Y immunoreactivity in pr ogressive supranuclear palsy. (1384261)	Litvan I.... Chase T.N.	1992	NPY
48	Glial fibrillary tangles with straight tubules in the brains of patients with progressive supranuclear palsy. (1436679)	Nishimura M.... Oda M.	1992	MAPT
49	Progressive supranuclear palsy: loss of choline-acetyltransferase-like immunoreactive neurons in the pontine reticular formation. (1922800)	Malessa S.... Agid Y.	1991	CHAT
50	Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. (1955905)	Atack J.R.... Chase T.N.	1991	BCHE, ACHE

Genes related to supranuclear palsy according to GeneCards:

(show top 50)    (show all 76)

id	Symbol	Description	Score	GeneCards Section Context
1	MAPT	microtubule-associated protein tau	11.1	Summaries, Publications
2	PSNP2	supranuclear palsy, progressive, 2	11.1	Publications, Aliases & Descriptions
3	PSNP3	Supranuclear palsy, progressive, 3	11.1	Publications, Aliases & Descriptions
4	NEFL	neurofilament, light polypeptide	11.0	Publications
5	PVALB	parvalbumin	11.0	Publications
6	RPS27A	ribosomal protein S27a	11.0	Publications
7	HCRT	hypocretin (orexin) neuropeptide precursor	11.0	Publications
8	CHAT	choline O-acetyltransferase	11.0	Publications
9	CRHR1	corticotropin releasing hormone receptor 1	11.0	Publications
10	CDK5	cyclin-dependent kinase 5	11.0	Publications
11	NDUFS4	NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa (NADH-coenzyme Q reductase)	11.0	Publications
12	ACHE	acetylcholinesterase	11.0	Publications
13	APOE	apolipoprotein E	11.0	Publications
14	LRRK2	leucine-rich repeat kinase 2	11.0	Publications
15	TH	tyrosine hydroxylase	11.0	Publications
16	DRD2	dopamine receptor D2	11.0	Publications
17	SLC6A3	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	11.0	Publications
18	SNCA	synuclein, alpha (non A4 component of amyloid precursor)	11.0	Publications
19	PARK2	parkinson protein 2, E3 ubiquitin protein ligase (parkin)	11.0	Publications
20	MIR132	microRNA 132	11.0	Publications
21	STH	saitohin	11.0	UniProt Related, Publications
22	SPPL2C	signal peptide peptidase like 2C	11.0	Publications
23	ACP2	acid phosphatase 2, lysosomal	11.0	Publications
24	RD3	retinal degeneration 3	11.0
25	CHRM4	cholinergic receptor, muscarinic 4	11.0	Publications
26	CD8B	CD8b molecule	11.0	Publications
27	WNT3	wingless-type MMTV integration site family, member 3	11.0	Publications
28	CHRM1	cholinergic receptor, muscarinic 1	11.0	Publications
29	BMS1	BMS1 homolog, ribosome assembly protein (yeast)	11.0	Publications
30	DDB2	damage-specific DNA binding protein 2, 48kDa	11.0	Publications
31	PGK1	phosphoglycerate kinase 1	11.0	Publications
32	MINK1	misshapen-like kinase 1	11.0	Publications
33	MOBP	myelin-associated oligodendrocyte basic protein	11.0	Publications
34	STX6	syntaxin 6	11.0	Publications
35	ALDOA	aldolase A, fructose-bisphosphate	11.0	Publications
36	TGM3	transglutaminase 3 (E polypeptide, protein-glutamine-gamma-glutamyltransferase)	11.0	Publications
37	IRF4	interferon regulatory factor 4	11.0	Publications
38	NPC1	Niemann-Pick disease, type C1	11.0	Publications
39	EIF2AK3	eukaryotic translation initiation factor 2-alpha kinase 3	11.0	Publications
40	NTS	neurotensin	11.0	Publications
41	CS	citrate synthase	11.0	Publications
42	IL21	interleukin 21	11.0	Publications
43	SLCO1A2	solute carrier organic anion transporter family, member 1A2	11.0	Publications
44	CHRM2	cholinergic receptor, muscarinic 2	11.0	Publications
45	SYP	synaptophysin	11.0	Publications
46	NSF	N-ethylmaleimide-sensitive factor	11.0	Publications
47	GLUD1	glutamate dehydrogenase 1	11.0	Publications
48	MTA2	metastasis associated 1 family, member 2	11.0
49	MAP4K4	mitogen-activated protein kinase kinase kinase kinase 4	11.0	Publications
50	GBA	glucosidase, beta, acid	11.0	Publications

Pathways related to supranuclear palsy according to GeneDecks:

(show all 40)

id	Pathway	Score	Top Affiliating Genes
1	Apoptosis and survival Role of CDK5 in neuronal death and survival10	10.6	CDK5, NGF
2	Development Leptin signaling via JAK/STAT and MAPK cascades10	10.6	MAPK3
3	Amine ligand-binding receptors38	10.4	CHRM2, CHRM4, HTR1A, DRD2
4	Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics34	10.3	STX6, TH, DRD2, CDK5
5	Alzheimers Disease Pathway36	10.2	MAPT, APOE, CDK5, APP, MAPK1
6	Transcription Receptor-mediated HIF regulation10	10.2	MAPK1, MAPK3
7	Reelin Pathway (Cajal-Retzius cells)36	10.2	APOE, CDK5, APP, MAPT, WNT3
8	Parkinsons disease20	10.1	LRRK2, PARK2, PARK7, CASP3, SNCA, NDUFS4
9	Development_EGFR signaling via small GTPases41	10.0	MYC, MAPK1, HRAS
10	Development ACM2 and ACM4 activation of ERK10	10.0	MAPK3, MAPK1, CHRM2, CHRM4, HRAS
11	Development_EPO-induced Jak-STAT pathway41	10.0	MYC, MAPK1, MAPK3
12	Development_ACM2 and ACM4 activation of ERK41	10.0	MAPK1, CHRM2, CHRM4, HRAS, MAPK3
13	Development_VEGF-family signaling41	10.0	VEGFA, HRAS, MAPK1
14	Pathway_PA16598005034	9.9	MYC, MAPK3, HRAS, MAPK1
15	Sympathetic Nerve Pathway (Neuroeffector Junction)34	9.9	NPY, CHAT, ACHE, TH
16	Cholinergic synapse20	9.8	MAPK1, CHRM4, CHRM2, ACHE, CHAT, HRAS
17	Development Dopamine D2 receptor transactivation of EGFR10	9.8	DRD2, HRAS, MAPK1
18	Thyroid cancer20	9.8	MAPK3, MAPK1, HRAS, MYC
19	Development_Dopamine D2 receptor transactivation of EGFR41	9.8	MAPK1, DRD2, MAPK3, HRAS
20	Development EPO-induced Jak-STAT pathway10	9.8	HRAS, MAPK3, MYC, MAPK1
21	Transcription_Receptor-mediated HIF regulation41	9.8	MAPK1, VEGFA, MAPK3, HRAS
22	Development EGFR signaling via small GTPases10	9.8	MYC, MAPK3, MAPK1, HRAS
23	Development VEGF-family signaling10	9.7	HRAS, MAPK1, MAPK3, VEGFA
24	Bladder cancer20	9.6	HRAS, MAPK1, MYC, VEGFA, MAPK3
25	Immune response IL-2 activation and signaling pathway10	9.6	HRAS, MYC, IL2, MAPK3, MAPK1
26	Apoptosis and survival_Role of CDK5 in neuronal death and survival41	9.6	MAPK3, CASP3, NGF, HRAS, MAPK1, CDK5
27	Immune response_IL-2 activation and signaling pathway41	9.6	MAPK3, HRAS, MAPK1, IL2, MYC
28	IL-2 Pathway36	9.6	HRAS, MAPK1, MAPK3, IL2, MYC
29	Development_Neurotrophin family signaling41	9.5	HRAS, NGF, MAPK3, MAPK1
30	TRKA Signaling36	9.5	MAPK3, MYC, HRAS, CASP3, MAPK1
31	Alzheimers disease20	9.5	MAPK1, CASP3, SNCA, NDUFS4, EIF2AK3, MAPK3
32	BDNF Pathway36	9.3	YWHAQ, MAPK3, MAPK1, HRAS
33	Development Neurotrophin family signaling10	9.2	MAPK3, MAPK1, HRAS, NGF
34	14-3-3 Induced Intracellular Signaling36	9.2	MAPK1, HRAS, YWHAQ, MAPK3, SNCA, MAPT
35	PEDF Induced Signaling36	9.2	IL21, CSF3, HRAS, MAPK1, MAPK3, IL2
36	MAPK signaling pathway20	9.2	MAPK1, MAPT, HRAS, MAPK3, MAP4K4, MYC
37	Neuroscience3	9.0	SYP, LRRK2, NEFL, NSF, TH, GFAP
38	IL-6 Pathway36	9.0	MAPK3, MYC, IL2, IL21, MAPK1, CSF3
39	STAT3 Pathway36	8.9	MYC, IL2, MAPK3, MAPK1, HRAS, CSF3
40	Endothelin-1 Signaling Pathway36	8.7	MAPK3, CSF3, HRAS, CASP3, MAPK1, IL21

Compounds related to supranuclear palsy according to GeneDecks:

(show top 50)    (show all 276)

id	Compound	Score	Top Affiliating Genes
1	carbachol32 9 9	12.4	CHRM2, CHRM1, SNCA, HCRT
2	levodopa32 9 9	12.0	NTS, SNCA, RPS27A, NDUFS4, LRRK2, TH
3	donepezil32 9 18 9	13.0	ACHE, APP, BCHE, CHAT, CHRM1, APOE
4	threonine32	9.9	GLUD1, MAP2, MAPT, CDK5, CHRM2, PARK2
5	olanzapine32 34 9 18 9	13.8	SLC6A3, NTS, DRD2, GLUD1, HTR3A, HTR1A
6	aspartate32	9.7	SLC6A3, HRAS, RPS27A, PVALB, TH, GFAP
7	glucose32	9.7	CDK5, EIF2AK3, ALDOA, HSPB2, GLUD1, PGK1
8	scopolamine32 9 18 9	12.6	BCHE, TSPO, ACHE, HTR1A, CHRM4, CHRM1
9	mptp32	9.6	DRD2, NDUFS4, SLC6A3, TH, TSPO, GFAP
10	clozapine32 34 9 9	12.3	CHRM1, PVALB, SLC6A3, CHRM4, DRD2, HTR3A
11	ethanol32 34 9 18 9	13.3	MAP2, ALDOA, NTS, SNCA, CRHR1, APOH
12	methamphetamine32 9 9	11.3	MAP2, DRD2, NTS, SNCA, RPS27A, CHAT
13	haloperidol32 34 9 9	12.2	SLC6A3, NPY, SYP, PVALB, CHAT, HTR1A
14	rotenone32	9.2	PARK2, PARK7, MAPK1, CASP3, SNCA, SLC6A3
15	h2o232	9.2	PRNP, SLC6A3, PGK1, SYP, TH, TSPO
16	atropine32 9 9	11.2	NPY, TH, ACHE, NGF, SNCA, NTS
17	tetrodotoxin32	9.1	HCRT, GFAP, TH, PVALB, NPY, NTS
18	4-hydroxynonenal32 18	9.9	MAPT, MAPK1, APOE, APP, MYC, CASP3
19	kainate32	8.6	CHAT, APOE, MAPT, MAP2, GFAP, TSPO
20	valine32	8.3	NGF, SNCA, HRAS, GLUD1, MAPT, TSPO
21	choline32 9 18 9	11.3	BCHE, CHRM2, CHAT, CHRM1, APP, MAPT
22	alanine32	8.2	MYC, PARK2, BCHE, CHRM2, CHAT, CHRM1
23	dopamine32 9 18 9	11.2	TH, PVALB, SYP, SLC6A3, MAPT, MAP2
24	6-hydroxydopamine32	8.1	PARK7, MYC, PARK2, CHAT, DRD2, CASP3
25	corticosterone32 18	9.1	NTS, APP, NPY, TH, HCRT, TSPO
26	nitric oxide32 9 18 9	11.1	HRAS, GBA, MAPK3, APOH, CHRM1, NTS
27	5-hydroxytryptamine32	8.1	CHRM2, HTR1A, CHRM1, SLC6A3, HTR3A, DRD2
28	glutamate32	8.1	PVALB, NSF, CS, NEFL, RPS27A, SNCA
29	paraffin32	8.0	NTS, PRNP, HRAS, SNCA, NPY, MAPT
30	cocaine32 9 9	9.9	TH, TSPO, GFAP, HCRT, NGF, CRHR1
31	gaba32 42	8.9	SLC6A3, NPY, SYP, PVALB, TH, TSPO
32	superoxide32 18	8.8	PRNP, NDUFS4, HRAS, GLUD1, CASP3, PARK7
33	estrogen32	7.7	PARK2, HRAS, MAPK3, MAP2, APOH, APOE
34	thapsigargin32 42	8.7	HCRT, APP, HSPB2, CASP3, NTS, NGF
35	paclitaxel32 34 9 9	10.6	PGK1, CSF3, VEGFA, MYC, PARK2, CDK5
36	atp32	7.5	PARK2, CHAT, CHRM1, MTAP, CDK5, APOH
37	testosterone32 9 18 9	10.5	HCRT, SNCA, GFAP, TSPO, SYP, TH
38	glutamine32	7.5	PARK2, CDK5, APOE, APP, NSF, SYP
39	norepinephrine32 9 18 9	10.5	SLC6A3, NPY, SYP, TH, TSPO, HCRT
40	adenylate32	7.3	CHRM2, CHRM1, MTAP, APP, MAP2, MAPK1
41	creatinine32	7.2	HSPB2, TSPO, BCHE, APOH, APP, MAPT
42	dexamethasone32 42 34 9 9	11.2	CRHR1, CSF3, VEGFA, NGF, RPS27A, NTS
43	arginine32	7.0	NPY, APOE, TSPO, HSPB2, CDK5, BCHE
44	acetylcholine32 9 18 9	9.8	BCHE, APP, APOE, CHRM4, CHRM1, CHAT
45	nmda32 42	7.7	DRD2, NTS, RPS27A, NGF, ACHE, HCRT
46	cisplatin32 34 9 9	9.6	DDB2, RPS27A, CSF3, SYP, GFAP, DRD2
47	vegf32	6.6	CSF3, IL2, APOE, APOH, APP, MAP2
48	serine32	6.5	GLUD1, CASP3, HSPB2, MAPK1, MAPK3, MAP4K4
49	calcium32 9 18 9	9.1	NDUFS4, APOH, MAP2, MAPK3, MAPK1, CDK5
50	tyrosine32	5.2	PARK2, HRAS, NTS, SNCA, CRHR1, RPS27A

Cellular components related to supranuclear palsy according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	axon terminus	GO:043679	10.1	CHRM4, CHRM1, CHRM2, DRD2
2	asymmetric synapse	GO:032279	9.9	CHRM2, CHRM1, CHRM4
3	neuronal cell body	GO:043025	9.8	CHAT, CHRM4, CDK5, CHRM2, MAP2, HTR3A
4	cell junction	GO:030054	9.7	SYP, HCRT, ACHE, SNCA, HTR3A, MINK1
5	axon	GO:030424	9.4	MAPT, CHAT, CDK5, MINK1, APP, NEFL
6	plasma membrane	GO:005886	7.5	CHRM2, CASP3, HTR3A, HTR1A, MAPT, APP
7	cytosol	GO:005829	7.2	CASP3, HRAS, HSPB2, ALDOA, MAPK1, MAPK3
8	cytoplasm	GO:005737	6.0	APOE, VEGFA, CASP3, GLUD1, HRAS, SNCA

Biological processes related to supranuclear palsy according to GeneDecks:

(show all 17)

id	Name	GO ID	Score	Top Affiliating Genes
1	activation of MAPKK activity	GO:000186	10.7	LRRK2
2	regulation of locomotion	GO:040012	10.6	CHRM1, SNCA, LRRK2
3	dopamine biosynthetic process	GO:042416	10.6	SLC6A3, TH, SNCA
4	adult walking behavior	GO:007628	10.5	DRD2, NPC1, MAPT, CHAT
5	synaptic transmission, dopaminergic	GO:001963	10.3	CDK5, DRD2, TH
6	regulation of long-term neuronal synaptic plasticity	GO:048169	10.3	DRD2, HRAS, SNCA, SYP
7	neurotransmitter biosynthetic process	GO:042136	10.2	SLC6A3, ACHE, TH
8	visual learning	GO:008542	10.1	DRD2, HRAS, APP, CDK5
9	adult locomotory behavior	GO:008344	9.9	NGF, APP, PARK7, SNCA
10	negative regulation of neuron apoptotic process	GO:043524	9.9	PARK7, PARK2, HRAS, SNCA, NGF
11	cell death	GO:008219	9.7	PARK7, PARK2, APOE, SLC6A3, GBA, SPG7
12	MAPK cascade	GO:000165	9.6	MAPK1, MAPK3, HRAS, MYC, LRRK2
13	neuron projection development	GO:031175	9.2	CDK5, MAP2, NGF, NPY, APP
14	response to drug	GO:042493	9.1	NPC1, MYC, PARK7, BCHE, CHAT, DRD2
15	central nervous system neuron development	GO:021954	9.1	CDK5, MAP2, NPY
16	synaptic transmission	GO:007268	8.8	NEFL, MAPK1, HTR3A, HRAS, ACHE, HCRT
17	positive regulation of cell proliferation	GO:008284	8.5	MYC, CHRM1, IL2, CSF3, VEGFA, HTR1A

Molecular functions related to supranuclear palsy according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	G-protein coupled acetylcholine receptor activity	GO:016907	10.1	CHRM1, CHRM2, CHRM4
2	tubulin binding	GO:015631	10.0	MAP2, ALDOA, PRNP, LRRK2
3	drug binding	GO:008144	9.7	CHRM2, HTR1A, DRD2, CHRM1, SLC6A3
4	identical protein binding	GO:042802	9.0	APOE, NEFL, APP, ALDOA, GLUD1, SMURF2
5	protein binding	GO:005515	4.2	NEFL, HRAS, DRD2, DDB2, SPG7, SNCA